JP2020534540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534540A5 JP2020534540A5 JP2020516740A JP2020516740A JP2020534540A5 JP 2020534540 A5 JP2020534540 A5 JP 2020534540A5 JP 2020516740 A JP2020516740 A JP 2020516740A JP 2020516740 A JP2020516740 A JP 2020516740A JP 2020534540 A5 JP2020534540 A5 JP 2020534540A5
- Authority
- JP
- Japan
- Prior art keywords
- napi2b
- cancer
- seq
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 21
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 21
- 239000000611 antibody drug conjugate Substances 0.000 claims description 17
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 17
- 206010033128 Ovarian cancer Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 206010038389 Renal cancer Diseases 0.000 claims description 10
- 201000010982 kidney cancer Diseases 0.000 claims description 10
- 208000009956 adenocarcinoma Diseases 0.000 claims description 8
- 230000004043 responsiveness Effects 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 5
- 206010004593 Bile duct cancer Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 238000010191 image analysis Methods 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 101710114425 Homeobox protein Nkx-2.1 Proteins 0.000 claims description 2
- 102100027893 Homeobox protein Nkx-2.1 Human genes 0.000 claims description 2
- 101710088547 Thyroid transcription factor 1 Proteins 0.000 claims description 2
- 101710159262 Transcription termination factor 1 Proteins 0.000 claims description 2
- 230000000762 glandular Effects 0.000 claims description 2
- 238000000386 microscopy Methods 0.000 claims description 2
- -1 napsin A Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 238000000399 optical microscopy Methods 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 1
- 210000001581 salivary duct Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762561107P | 2017-09-20 | 2017-09-20 | |
| US62/561,107 | 2017-09-20 | ||
| US201762571397P | 2017-10-12 | 2017-10-12 | |
| US62/571,397 | 2017-10-12 | ||
| US201862718692P | 2018-08-14 | 2018-08-14 | |
| US62/718,692 | 2018-08-14 | ||
| PCT/US2018/051951 WO2019060542A2 (en) | 2017-09-20 | 2018-09-20 | COMPOSITIONS AND METHODS FOR PREDICTING RESPONSE TO NAPI2B TARGETING THERAPY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534540A JP2020534540A (ja) | 2020-11-26 |
| JP2020534540A5 true JP2020534540A5 (https=) | 2021-10-28 |
| JP7279026B2 JP7279026B2 (ja) | 2023-05-22 |
Family
ID=63963394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516740A Active JP7279026B2 (ja) | 2017-09-20 | 2018-09-20 | Ｎａｐｉ２ｂ標的化療法に対する応答を予測するための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11596694B2 (https=) |
| EP (1) | EP3685166A2 (https=) |
| JP (1) | JP7279026B2 (https=) |
| KR (1) | KR20200055770A (https=) |
| CN (1) | CN111492246A (https=) |
| AU (1) | AU2018337947A1 (https=) |
| BR (1) | BR112020005390A2 (https=) |
| CA (1) | CA3075798A1 (https=) |
| IL (1) | IL273252B2 (https=) |
| MX (1) | MX2020003214A (https=) |
| TW (1) | TW201929906A (https=) |
| WO (1) | WO2019060542A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210049122A (ko) | 2018-08-17 | 2021-05-04 | 메르사나 테라퓨틱스, 인코포레이티드 | NaPi2b 표적화 폴리머 항체-약물 접합체 및 이것의 사용 방법 |
| CA3149482A1 (en) | 2019-08-02 | 2021-02-11 | Mersana Therapeutics, Inc. | Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer |
| CN114641316A (zh) | 2019-10-30 | 2022-06-17 | Cis制药股份公司 | 用于递送活性剂的生物相容性聚合物药物载体 |
| IL294321B1 (en) | 2020-01-09 | 2026-04-01 | Mersana Therapeutics Inc | Antibody-drug conjugates are attached at a specific site with linkers that include peptides. |
| WO2021202984A1 (en) | 2020-04-02 | 2021-10-07 | Mersana Therapeutics, Inc. | Antibody drug conjugates comprising sting agonists |
| WO2022032228A1 (en) | 2020-08-07 | 2022-02-10 | The Broad Institute, Inc. | Therapeutic targeting of phosphate dysregulation in cancer via the xpr1:kidins220 protein complex |
| JP7589759B2 (ja) * | 2021-02-08 | 2024-11-26 | 株式会社島津製作所 | 推定装置 |
| EP4605426A1 (en) * | 2022-10-19 | 2025-08-27 | Zymeworks BC Inc. | Antibody-drug conjugates targeting napi2b and methods of use |
| CA3266931A1 (en) * | 2022-10-19 | 2024-04-25 | Zymeworks Bc Inc. | ANTI-NAPI2B ANTIBODIES AND METHODS OF USE |
| TW202530268A (zh) * | 2023-10-19 | 2025-08-01 | 加拿大商酵活英屬哥倫比亞有限公司 | 抗ｎａｐｉ２ｂ抗體－藥物結合物及使用方法 |
| WO2025199352A2 (en) * | 2024-03-20 | 2025-09-25 | Juno Therapeutics, Inc. | Antibodies specific for solute carrier family 34 member 2 (slc34a2) |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3900534A1 (de) * | 1989-01-10 | 1990-07-12 | Boehringer Mannheim Gmbh | Diagnostischer nachweis unter verwendung von chimaeren antikoerpern |
| CH694588A5 (de) | 1999-02-09 | 2005-04-15 | Hoffmann La Roche | Menschliche intestinale Npt2B. |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| WO2003060086A2 (en) | 2002-01-15 | 2003-07-24 | Board Of Regents, The University Of Texas System | Napi type iib polypeptides and methods for making and using same |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| WO2005101017A1 (en) * | 2004-04-07 | 2005-10-27 | Genentech, Inc. | Mass spectrometry of antibody conjugates |
| KR20120064120A (ko) * | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| US8383799B2 (en) * | 2006-01-20 | 2013-02-26 | Cell Signaling Technology, Inc. | Translocation and mutant ROS kinase in human non-small cell lung carcinoma |
| CN101568349B (zh) | 2006-10-25 | 2012-09-19 | 威斯康星大学校友研究基金会 | 减少磷酸盐吸收的方法 |
| WO2009097128A1 (en) * | 2008-01-29 | 2009-08-06 | Ludwig Institute For Cancer Research Ltd. | Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy |
| US8742076B2 (en) | 2008-02-01 | 2014-06-03 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| CN102159248B (zh) | 2008-07-15 | 2013-09-11 | 健泰科生物技术公司 | 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途 |
| JP5370826B2 (ja) | 2009-04-20 | 2013-12-18 | 株式会社パソロジー研究所 | 癌の組織型を判別するカクテル抗体、判別キット及び判別方法 |
| BR112012012750A2 (pt) | 2009-11-30 | 2020-08-11 | Genentech Inc | anticorpo isolado, célula, ácido nucleíco isolado e método |
| JP5827327B2 (ja) | 2010-07-07 | 2015-12-02 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| JP5823514B2 (ja) | 2010-07-07 | 2015-11-25 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| WO2012006477A1 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| EP2590655B1 (en) | 2010-07-07 | 2015-06-24 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| JP6087289B2 (ja) | 2010-12-14 | 2017-03-01 | レセプタ バイオファーマ エス．エー． | Ｎａｐｉ２ｂ輸送体に対するヒト化モノクローナル抗体の相補性決定領域に由来する抗腫瘍ペプチド |
| WO2012171020A1 (en) * | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EA032231B1 (ru) | 2013-10-11 | 2019-04-30 | Мерсана Терапьютикс, Инк. | Конъюгаты белок-полимер-лекарственное средство |
| CA2927022C (en) | 2013-10-11 | 2018-08-21 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
| IL248408B (en) * | 2014-04-25 | 2022-06-01 | Exelixis Inc | A method for treating adenocarcinoma of the lungs |
| TWI695011B (zh) * | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗ｈｅｒ２表位之單株抗體及其使用之方法 |
| CA2988115A1 (en) | 2015-06-03 | 2016-12-08 | Bristol-Myers Squibb Company | Anti-gitr antibodies for cancer diagnostics |
| WO2017008169A1 (en) * | 2015-07-15 | 2017-01-19 | Zymeworks Inc. | Drug-conjugated bi-specific antigen-binding constructs |
| JP7023841B2 (ja) | 2015-10-23 | 2022-02-22 | エフ．ホフマン－ラ ロシュ アーゲー | マーカー分子に基づいて個体を化学療法により処置すべきであると同定する方法および関連する使用 |
| US20170261766A1 (en) | 2016-03-14 | 2017-09-14 | Vance M. Thompson | Contact lens with flexible center and rigid periphery |
| WO2017160753A1 (en) | 2016-03-14 | 2017-09-21 | The Penn State Research Foundation | Novel selenazolidine and thiazolidine compounds for treating cancer and other diseases |
| CN109310885B (zh) | 2016-03-15 | 2022-05-31 | 梅尔莎纳医疗公司 | NaPi2b靶向抗体-药物缀合物及其使用方法 |
| JP7320458B2 (ja) | 2017-06-22 | 2023-08-03 | メルサナ セラピューティクス インコーポレイテッド | 薬物担持ポリマースキャフォールドおよびタンパク質－ポリマー－薬物コンジュゲートを製造する方法 |
-
2018
- 2018-09-20 EP EP18792596.1A patent/EP3685166A2/en not_active Withdrawn
- 2018-09-20 IL IL273252A patent/IL273252B2/en unknown
- 2018-09-20 US US16/136,706 patent/US11596694B2/en active Active
- 2018-09-20 MX MX2020003214A patent/MX2020003214A/es unknown
- 2018-09-20 KR KR1020207011297A patent/KR20200055770A/ko not_active Abandoned
- 2018-09-20 CA CA3075798A patent/CA3075798A1/en active Pending
- 2018-09-20 CN CN201880074734.0A patent/CN111492246A/zh active Pending
- 2018-09-20 AU AU2018337947A patent/AU2018337947A1/en not_active Abandoned
- 2018-09-20 BR BR112020005390-2A patent/BR112020005390A2/pt not_active IP Right Cessation
- 2018-09-20 TW TW107133186A patent/TW201929906A/zh unknown
- 2018-09-20 JP JP2020516740A patent/JP7279026B2/ja active Active
- 2018-09-20 WO PCT/US2018/051951 patent/WO2019060542A2/en not_active Ceased
-
2023
- 2023-01-26 US US18/160,012 patent/US20230355787A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534540A5 (https=) | ||
| IL273252B2 (en) | Compositions and methods for predicting response to napi2b-targeted therapy | |
| CN105392800A (zh) | 抗cxcl1、cxcl7和cxcl8抗体及其应用 | |
| ES2753360T3 (es) | Anticuerpos contra PD-L1 y usos de los mismos | |
| CN103154741B (zh) | 含有抗体作为成分的医药品的有效性的判定方法 | |
| TR201802659T4 (tr) | Folr1 kanser terapisinin etkinliğini arttırmak için yöntemler. | |
| JP2015533788A5 (https=) | ||
| JP2015529199A5 (https=) | ||
| CN104755501A (zh) | 与赖氨酰氧化酶样蛋白2(loxl2)相关的治疗和诊断方法 | |
| DK2694972T3 (en) | PROCEDURES FOR PREVENTING AND IMPROVING GASTRIC CANCER SURVIVAL | |
| US20210341490A1 (en) | Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies | |
| JP2013517258A (ja) | ベバシズマブ併用治療のための腫瘍組織に基づくバイオマーカー | |
| JP6940505B2 (ja) | 組成物および癌の発生リスクの評価方法 | |
| JP2014523920A5 (https=) | ||
| RU2017136863A (ru) | Способы лечения рака легкого | |
| WO2018178307A1 (en) | Improved immunogenicity assays | |
| EA037015B1 (ru) | Применение и способ для профилактики или лечения рака яичников с использованием композиции, содержащей прогастринсвязывающее антитело | |
| JP2019537619A5 (https=) | ||
| JP2016540993A (ja) | タンパク質生体マーカー及びその使用 | |
| EA037027B1 (ru) | Применение и способ для профилактики или лечения рака желудка с использованием композиции, содержащей моноклональное прогастринсвязывающее антитело | |
| WO2018011344A1 (en) | Method and means for detecting the level of total vegf-a | |
| JP2018516877A5 (https=) | ||
| JP2018520366A5 (https=) | ||
| US12433951B2 (en) | Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin | |
| JP2026509486A (ja) | 神経変性障害を診断および処置する方法 |